$HARP News
Last published 2y ago
- 2y agoHARPSeismic Therapeutic Appoints Julie Eastland as Independent Board DirectorBusiness WireSeismic Therapeutic, Inc., the machine learning immunology company, today announced that Julie Eastland has been appointed as Independent Director to Seismic's Board. Ms. Eastland brings more than 30 years of experience
- 2y agoHARPMRKMerck Completes Acquisition of Harpoon Therapeutics, Inc.Business WireAcquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager Merck (NYSE:MRK), known as MSD
- 2y agoMRKHARPMerck results beat expectations as top drugs Keytruda, Gardasil post strong salesCNBCMerck still posted a quarterly loss due to previously announced charges associated with its cancer drug collaboration deal with Daiichi Sankyo.
- 2y agoHAHARPICVXPXDKuehn Law Encourages HA, ICVX, PXD, and HARP Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoAMAMHARPAXNXCPEKuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoHARPHARP Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Harpoon Therapeutics to MerckGlobeNewswireMONSEY, N.Y., Jan. 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $23.00 per share in cash pursuant to which Harpoon Therapeutics, Inc. (NASDAQ:HARP)
- 2y agoHARPMRKMerck to Acquire Harpoon Therapeutics, Further Diversifying Oncology PipelineBusiness WireAcquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors Merck (NYSE:MRK), known as
- 2y agoHARPHarpoon Therapeutics Strengthens Leadership TeamGlobeNewswireJames Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage
- 2y agoHARPHarpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers SymposiumGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and
- 2y agoHARPHarpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)GlobeNewswire• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy • At
- 3y agoHARPHarpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireOctober 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung cancer (SCLC) and other
- 3y agoHARPHarpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and
- 3y agoHARPHarpoon Therapeutics Announces Up to $150 Million Private PlacementGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP) (the "Company"), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it
- 3y agoHARPHarpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023GlobeNewswireConfirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete responses 32% (6/19) confirmed response rate in patients with small
- 3y agoHARPHarpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a live
- 3y agoHARPHarpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present
- 3y agoHARPHarpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual MeetingGlobeNewswireTarget dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome (CRS), No ICANS – Phase 1 data set, including recommended Phase 2 dose(s) (RP2D), to
- 3y agoHARPHarpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination CohortGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first
- 3y agoHARPHarpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVieGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has
- 3y agoHARPHarpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance
- 3y agoHARPHarpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023GlobeNewswireKOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for poster presentation at the European Society for Medical Oncology
- 3y agoHARPHarpoon Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will
- 3y agoHARPHarpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireAbstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society (IMS) Annual Meeting and the European Society for Medical Oncology (ESMO) in the fall Enrollment for HPN328 (DLL3) ongoing;
- 3y agoHARPHarpoon Therapeutics to Participate in Two Upcoming Investor Conferences in AugustGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will
- 3y agoHARPReplicate Bioscience Appoints Rachael Lester as Chief Business OfficerPR NewswireBiopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team SAN DIEGO, July 10, 2023 /PRNewswire/ -- Replicate Bioscience, a
- 3y agoHARPHarpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple MyelomaGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the completion of
- 3y agoHARPHarpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireEnrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023 Five preclinical posters presented at AACR
- 3y agoHARPHarpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023GlobeNewswirePreclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor activityγ-secretase
- 3y agoHARPHarpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented preclinical data on
- 3y agoHARPHarpoon Therapeutics to Participate in the Canaccord Horizons in Oncology ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that Julie Eastland,
- 3y agoHARPHarpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswireHPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million preferred equity
- 3y agoHARPHarpoon Therapeutics Announces Closing of $25 Million Private PlacementGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP) (the "Company"), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that
- 3y agoHARPHarpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023GlobeNewswirePreclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform and
- 3y agoHARPHarpoon Therapeutics to Participate in the SVB Securities Global Biopharma ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will
- 3y agoHARPHarpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple MyelomaGlobeNewswireClinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest
- 3y agoHARPHarpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a
- 3y agoHARPHarpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will
- 3y agoHARPHarpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial ResultsGlobeNewswireHPN217 (BCMA) interim data update at ASH 2022; HPN328 (DLL3) exploring dosing regimens and HPN601 (EpCAM) expected to enter the clinic in 2023 Strategic realignment to focus resources on ongoing clinical programs;
- 4y agoHARPHarpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and ExpositionGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present
- 4y agoHARPHarpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Luke Walker, M.D., as Chief Medical O
- 4y agoHARPHarpoon Therapeutics Appoints Lauren Silvernail to Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Lauren Silvernail to its Board of Di
- 4y agoHARPHarpoon Therapeutics to Participate in Three Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in three upcoming invest
- 4y agoHARPHarpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswirePresented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting Portfolio prioritization and resource alignment strengthens support for the advancement of HPN328, HPN21
- 4y agoHARPHarpoon Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor
- 4y agoHARPHarpoon Therapeutics Expands Leadership TeamGlobeNewswireAppointments named for two key executive leadership positions in human resources and translational medicine SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy com
- 4y agoHARPHarpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual MeetingGlobeNewswireClinically active and well tolerated in patients with solid tumors Favorable safety profile emerging: 22% of patients experienced Grade 1-2 cytokine release syndrome (CRS); no Grade 3 or higher CRS One confirmed partial response; 27% of small cell lun
- 4y agoHARPHarpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the first quarter ended March 31, 2022
- 4y agoHARPHarpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung CancerGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a clinical supply agreement with F
- 4y agoHARPHarpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release SyndromeGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with preclinical data for its TriTAC-XR T cell e
- 4y agoHARPHarpoon Therapeutics Announces Leadership ChangeGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that Natalie Sacks, M.D., Chief Medical Officer, will be